Advocacy organizations are instrumental in helping us deepen our connections with and learn from the community. We are committed to building lasting relationships with organizations that share our vision and goals to change the lives of the people we aim to serve.

At SpringWorks, we are focusing on forging meaningful collaborations with academic institutions and industry partners to unleash the full potential of every molecule so we can develop and deliver life-changing medicines for people with cancer who are counting on us. The answers are waiting – let’s go find them.

SpringWorks entered into a clinical collaboration with GSK to conduct a Phase 2 randomized DREAMM-5 study evaluating nirogacestat in combination with GSK’s belamaf, an anti BCMA antibody-drug conjugate, in patients with relapsed or refractory multiple myeloma. Additional sub-studies evaluating nirogacestat plus belamaf in combination with standard of care agents are also ongoing.¹ Read more

SpringWorks entered into a clinical collaboration with Janssen Biotech, Inc. to conduct a Phase 1 study to evaluate nirogacestat in combination with Janssen’s investigational BCMA CD3 bispecific antibody, teclistamab, in patients with relapsed or refractory multiple myeloma. Read more

SpringWorks entered into a clinical collaboration with Pfizer to conduct a Phase 1b/2 study to evaluate nirogacestat in combination with Pfizer’s investigational BCMA CD3 bispecific antibody, elranatamab, in patients with relapsed or refractory multiple myeloma. Read more

SpringWorks entered into a clinical collaboration with AbbVie to conduct a Phase 1b study to evaluate nirogacestat in combination with AbbVie’s investigational CD3 bispecific antibody directed against BCMA, ABBV-383, in patients with relapsed or refractory multiple myeloma. Read more

SpringWorks entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate nirogacestat in combination with Regeneron’s investigational BCMAxCD3 bispecific antibody, linvoseltamab (REGN5458), in patients with relapsed or refractory multiple myeloma. Read more

SpringWorks entered into a sponsored research collaboration with the Dana-Farber Cancer Institute to further evaluate nirogacestat’s ability to modulate BCMA and potentiate BCMA-targeted therapies in a variety of preclinical multiple myeloma models. Read more

SpringWorks entered into a sponsored research agreement with the Fred Hutchinson Cancer Research Center to further evaluate nirogacestat’s ability to modulate BCMA and potentiate BCMA-targeted therapies in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch. Read more

SpringWorks entered into a clinical collaboration with BeiGene to evaluate BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283), in combination with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. Read more

SpringWorks and BeiGene announced the formation of MapKure, a clinical-stage company developing BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating BRAF mutations, including V600 BRAF mutations, non-V600 BRAF mutations, and RAF fusions. Read more

SpringWorks entered into a research collaboration agreement with Inserm Transfert, acting as a delegatee of the French National Institute of Health and Medical Research (Inserm), to explore the ability of nirogacestat to delay the development of resistance to the EGFR inhibitor osimertinib in preclinical models of non-small cell lung cancer (NSCLC) driven by the EGFR C797S gatekeeper mutation.

SpringWorks entered into a research collaboration agreement with the University of Eastern Finland to conduct novel computational biology research to characterize the effector protein dynamics of different RAS mutations. The objective of the collaboration is to understand the biological consequences of KRAS-effector protein interactions and downstream oncogenic signaling to guide patient selection strategies and explore novel targets.

SpringWorks entered into a research collaboration with the University of Zurich to further explore the activity of mirdametinib and lifirafenib combination therapy in preclinical patient-derived NRAS-mutant in vitro and in vivo solid tumors models.